HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

omega-Chloroacetophenone (Mace)

Subscribe to New Research on omega-Chloroacetophenone

A potent eye, throat, and skin irritant. One of its uses is as a riot control agent.

Also Known As:

Mace; Chloroacetophenone; 2-Chloro-1-phenylethanone; 3'-Chloroacetophenone; Chloracetophenone; 2 Chloro 1 phenylethanone; 2 Chloroacetophenone; alpha Chloroacetophenone; omega Chloroacetophenone; 2-Chloroacetophenone; alpha-Chloroacetophenone; Ethanone, 2-chloro-1-phenyl-

Networked: 2075 relevant articles (55 outcomes, 215 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Ketones: 431
  - Acetophenones: 13
    - omega-Chloroacetophenone: 2075
      - 4-chloroacetophenone
      - pentachloroacetophenone

Experts

1.	Serruys, Patrick W: 67 articles (12/2015 - 06/2003)
2.	Stone, Gregg W: 51 articles (01/2016 - 05/2002)
3.	Colombo, Antonio: 47 articles (12/2015 - 07/2003)
4.	Jeong, Myung Ho: 45 articles (11/2015 - 09/2003)
5.	Xu, Bo: 45 articles (08/2015 - 08/2005)
6.	Mehran, Roxana: 39 articles (01/2016 - 05/2002)
7.	Waksman, Ron: 37 articles (12/2015 - 01/2002)
8.	Pichard, Augusto D: 31 articles (12/2015 - 01/2002)
9.	Satler, Lowell F: 29 articles (12/2015 - 01/2002)
10.	Torguson, Rebecca: 29 articles (12/2015 - 07/2005)

Related Diseases

1.	Hemorrhage 09/01/2014 - "At 30 days, TRA compared to TFA was associated with a significant reduction of cardiovascular mortality (5.2% vs 10.5%; P<.001), significant MACE reduction (7.3% vs 12.5%; P<.001), fewer access-site complications (0.9% vs 8.2%; P<.001), and lower TIMI major bleeding (1.1% vs 4.3%; P<.001). " 01/01/2014 - "After multivariate adjustment we observed no improvement in MACE or survival and an increased risk of major bleeding." 07/01/2015 - "In randomized control trials and meta-analyses in patients with acute MI undergoing PCI, the radial artery (RA) approach compared to the femoral artery (FA) approach has shown to safely reduce access site related bleeding, length of hospitalization, and major adverse cardiac event (MACE) rates. " 12/01/2014 - "Study end points were: major and minor bleeding, port-of-entry complications, major adverse cardiac events (MACE) in-hospital, and at long-term follow-up. " 08/01/2009 - "The primary end-points of the trial (NACE) include major adverse cardiovascular events (MACE) and major bleeding. "
2.	Myocardial Infarction 07/01/2013 - "TRA was associated with a reduction in the rate of post-PCI myocardial infarction (2.3% versus 3.6% for TFA, p=0.023) and with a significant reduction of MACE (3.8% versus 5.2% for TFA, p=0.041). " 09/01/2003 - "The improvement in MACE was due to differences in rates of recurrent angina, without significant differences in death and myocardial infarction. " 12/01/1999 - "Only the group of operators performing <50 cases annually had a major adverse cardiac event (MACE) (death, myocardial infarction or symptom-driven revascularization) rate at one month significantly greater than predicted from baseline characteristics. " 05/01/2011 - "The c statistic for predicting MACE was 0.61 for clinical Thrombolysis In Myocardial Infarction risk score and improved to 0.84 by adding CT CAD data and improved further to 0.91 by adding RWMA (both p < 0.0001). " 01/01/2016 - "The aim of this study was to demonstrate the influence of HbA1c level at admission on the incidence of major adverse cardiac events (MACE) in prediabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). "
3.	Thrombosis (Thrombus) 04/01/2015 - "This interim analysis of the ABSORB EXTEND study shows low rates of MACE and scaffold thrombosis. " 03/01/2014 - "In the current study, large thrombus burden is not an independent predictor of 1-year cumulative MACE in STEMI patients who were treated with emergent PCI." 06/01/2015 - "Patients were grouped according to whether PD was performed or not, and the one-year incidences of MACE and scaffold thrombosis were compared. " 12/05/2013 - "In this meta-analysis, IVUS guidance in DES implantation appears to reduce MACE, mortality and MI, possibly by reducing thrombosis rather than restenosis rate. " 12/05/2013 - "IVUS guidance was associated with a significantly lower rate of MACE (RR=0.80, 95% CI 0.71–0.89, p b 0.001), death (RR=0.60, 95% CI 0.48–0.74, p b 0.001), MI (RR=0.59, 95% CI 0.44–0.80, p=0.001) and thrombosis (RR=0.50, 95% CI 0.32–0.80, p=0.007) and larger MLD (SMD=0.15, 95% CI 0.03 to 0.27, p=0.014), but not of revascularization (RR=0.95, 95% CI 0.82–1.09, p=0.75). "
4.	Death (Near-Death Experience) 01/01/2015 - "Long-term statin therapy dramatically reduced the rates of both MACE and all-cause death/cardiac death (by 20.5% and 28.6%/27.7%, resp.) in CAD and CKD patients. " 05/01/2005 - "At follow up, group 1 had improved global LV ejection fraction (48.7% v 43.6%, p < 0.001) and LV indexed end diastolic and end systolic volumes (75 v 86 ml/m(2) and 40 v 53 ml/m(2), respectively, p = 0.011) compared with group 2. Kaplan-Meier analysis showed a higher incidence of cardiac death (p = 0.02) and MACE (p < 0.0001) in group 2. TIMI 3 after PTCA was an independent predictor of event-free survival at follow up. " 02/01/2011 - "In a large observational registry with admitted potential for selection bias and residual confounding, DES in DM patients with coronary bifurcation lesions were associated with improved outcomes in terms of MACE, cardiac death, and repeat revascularization at long-term follow up. " 01/01/2009 - "MACE [cardiac death (CD) and hospitalization for angina (HA)] were the study end points. " 01/15/2016 - "At 9months, the TLR rate was 7.0% (13/187) whereas the rates for MACE, MI and cardiac death were 10.7% (20/187), 4.8% (9/187) and 2.1% (4/187) respectively. "
5.	Stroke (Strokes) 10/01/2008 - "OPCAB was associated with a significant reduction in operative mortality (adjusted odds ratio [AOR], 0.68; p = 0.045), stroke (AOR, 0.48; p < 0.001), and MACE (AOR, 0.66; p = 0.018). " 09/11/2007 - "Among women, OPCAB was associated with a significant reduction in death (OR 0.39, P=0.001), stroke (OR 0.43, P=0.002) and MACE (OR 0.43, P<0.001). " 03/01/2009 - "OPCAB was associated with reduced incidence of stroke (AOR = 0.51, P < 0.001) and MACE (AOR = 0.66, P = 0.002), whereas LMD was associated with an increased incidence of MACE (AOR = 1.24, P = 0.038). " 07/01/2015 - "This study aims to evaluate temporal changes in stroke complications and their association with mortality and MACE outcomes in a national cohort of patients undergoing percutaneous coronary interventions (PCIs) in England and Wales. " 05/01/2014 - "The purpose of the present study is to assess the potential risk factors for stroke and major adverse cardiac events (MACE) in a large population of Chinese AF patients presenting to emergency department. "

Related Drugs and Biologics

1.	tirofiban (Aggrastat)
2.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
3.	glucuronyl glucosamine glycan sulfate (Vessel)
4.	clopidogrel (Plavix)
5.	Glycoproteins (Glycoprotein)
6.	bivalirudin (Angiomax)
7.	Heparin (Liquaemin)
8.	Dalteparin (Dalteparin Sodium)
9.	Aspirin (Acetylsalicylic Acid)
10.	Enoxaparin (Lovenox)

Related Therapies and Procedures

1.	Stents
2.	Drug-Eluting Stents
3.	Enema (Enemas)
4.	Drug Therapy (Chemotherapy)
5.	Angioplasty (Angioplasty, Transluminal)